Prostate-specific antigen (PSA), the most commonly used biomarker, is not reliable for the detection and risk stratification of prostate cancer, because numerous prostate conditions, such as benign prostate hyperplasia (BPH), prostatitis and urinary tract infection, can cause a rise in PSA levels [3,4,5]. Here, KLK3 is linked to urogenital neoplasm.